- Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?2015 | First Faculty of Medicine
- Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody - Associated Vasculitis2018 | First Faculty of Medicine
- Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis2015 | First Faculty of Medicine
- Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives2020 | First Faculty of Medicine
- Avacopan jako přídatná terapie ANCA asociované vaskulitidy2020 | First Faculty of Medicine
- Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody - associated vasculitis: a randomized controlled trial2010 | First Faculty of Medicine
- Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis2008 | First Faculty of Medicine
- Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis2008 | Publication without faculty affiliation
- Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis Involving the Aortic Valve in a Twelve-year-old Girl2021 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis.2009 | First Faculty of Medicine
- Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial2009 | First Faculty of Medicine
- Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis2017 | First Faculty of Medicine
- Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multinational Retrospective Study2023 | First Faculty of Medicine
- Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations2023 | First Faculty of Medicine
- Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis2020 | First Faculty of Medicine
- Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis Should Type of ANCA Guide the Treatment?2020 | First Faculty of Medicine
- Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?2015 | First Faculty of Medicine
- Rapidly progressive glomerulonephritis - innovations in therapy2015 | First Faculty of Medicine
- Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial2019 | First Faculty of Medicine
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis2017 | First Faculty of Medicine
- Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis2015 | First Faculty of Medicine
- ANCA-Associated Renal Vasculitis - An Update2013 | First Faculty of Medicine
- Current treatment strategies in ANCA-positive renal vasculitis - lessons from European randomized trials2003 | First Faculty of Medicine
- Optimizing the Therapeutic Strategies in ANCA - Associated Vasculitis - Single Centre Experience with International Randomized Trials2006 | First Faculty of Medicine
- Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience2004 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab2021 | First Faculty of Medicine
- ANCA Vasculitis Induction Management During the COVID-19 Pandemic2021 | First Faculty of Medicine
- Plasma exchange in ANCA-associated vasculitis: the pro position2021 | First Faculty of Medicine
- Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?2021 | First Faculty of Medicine
- Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts2017 | First Faculty of Medicine